DNA encoding human papillomavirus type 6A

• US 6,290,965 B1
• Filed: 03/08/2000
• Issued: 09/18/2001
• Est. Priority Date: 09/22/1994
• Status: Expired due to Term

• Current Assignee: Merck Sharp & Dohme Corporation (Merck & Co., Inc.)
• Original Assignee: Merck & Co., Inc.
• Inventors: Jansen, Kathrin U., Hofmann, Kathryn J.
• Primary Examiner(s): SALIMI, ALI REZA
• Application Number:
  US09/521,526
• Time in Patent Office: 559 Days
• Field of Search: 424/704.1, 424/199.1, 424/186.1, 435/91.1, 435/91.33, 435/235.1, 435/325, 435/239, 435/320.1, 514/44, 536/23.72, 536/23.1
• US Class Current: 424/199.1
• CPC Class Codes: A61K 2039/51 comprising whole cells, viruses or DNA/RNA
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2710/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

The present invention is directed to DNA molecules encoding purified human papillomavirus type 6a and compounds derived therefrom.

Claims

1. An isolated DNA encoding a single HPV6a protein, wherein the HPV6a protein is selected form the group consisting of:

HPV6a L2 (encoded by nucleotides 4380-5804 of SEQ ID NO;

2), HPV6a E1 (encoded by nucleotides 717-2781 of SEQ ID NO;

2), HPV6a E2 (encoded by nucleotides 2697-3829 of SEQ ID NO;

2), HPV6a E4 (encoded by nucleotides 3242-3584 of SEQ ID NO;

2), HPV6a E5 (encoded by nucleotides 3242-3584 of SEQ ID NO;

2), HPV6a E6 (encoded by nucleotides 32-554 of SEQ ID NO;

2), and HPV6a E7 (encoded by nucleotides 442-826 of SEQ ID NO;

2), wherein the DNA is under transcriptional control of a heterologous promoter.

2. A vector comprising DNA encoding a single human Papillomavirus 6a (HPV6a) protein, wherein the DNA consists of a sequence selected from the group consisting of:

HPV6a L2 (nucleotides 4380-5804 of SEQ ID NO;

2), HPV6a E1 (nucleotides 717-2781 of SEQ ID NO;

2), HPV6a E2 (nucleotides 2697-3829 of SEQ ID NO;

2), HPV6a E4 (nucleotides 3242-3584 of SEQ ID NO;

2), HPV6a E5 (nucleotides 3888-4163 of SEQ ID NO;

2), HPV6a E6 (nucleotides 32-554 of SEQ ID NO;

2), and HPV6a E7 (nucleotides 442-826 of SEQ ID NO;

2).

3. A host cell comprising a vector according to claim 2.

4. A host cell according to claim 3 which is selected from the group consisting of:

yeast, insect, and mammalian cells.

5. A host cell according to claim 4 which is a yeast cell.

6. An immunogenic composition comprising DNA encoding a single HPV6a protein, wherein the BPV6a protein is selected from the group consisting of:

HPV6a L2 (encoded by nucleotides 4380-804 of SEQ ID NO;

2), HPV6a E1 (encoded by nucleotides 717-2781 of SEQ ID NO;

2), HPV6a E2 (encoded by nucleotides 2697-3829 of SEQ ID NO;

2), HPV6a E4 (encoded by nucleotides 3242-3584 of SEQ ID NO;

2), HPV6a E5 (encoded by nucleotides 3242-3584 of SEQ ID NO;

2), HPV6a E6 (encoded by nucleotides 32-554 of SEQ ID NO;

2), and HPV6a E7 (encoded by nucleotides 442-826 of SEQ ID NO;

2).

7. An immunogenic composition according to claim 6, wherein the DNA encoding the HPV6a protein are present in a vector.

8. An immunogenic composition according to claim 7 wherein the composition is formulated with an immunologically acceptable carrier.

9. A method of making a protein composition comprising:

a) transferring a vector comprising a DNA encoding a single HPV 6a protein selected form the group consisting of;

HPV6a L2 (nucleotides 4380-5804 of SEQ ID NO;

2), HPV6a E1 (nucleotides 717-2781 of SEQ ID NO;

2), HPV6a E2 (nucleotides 2697-3829 of SEQ ID NO;

2), HPV6a E4 (nucleotides 3242-3584 of SEQ ID NO;

2), HPV6a E5 (nucleotides 3242-3584 of SEQ ID NO;

2), HPV6a E6 (nucleotides 32-554 of SEQ ID NO;

2), and HPV6a E7 (nucleotides 442-826 of SEQ ID NO;

2) to a host cell, and

b) culturing the host cell under conditions which allow expression of the HPV6a protein from the vector.

10. A method according to claim 9 wherein the host cell is selected from the group consisting of:

yeast, insect, and mammalian cells.

11. A method according to claim 10, further comprising the step of purifying the protein so produced.

12. A method according to claim 10, further comprising the step of formulating the protein with an immunologically acceptable carrier.